在HER2阳性固体癌症中实施抗体药物合物:最近的进展和未来的方向
Jiazheng Yu1, Mingyang Li1, Xiandong Liu1
1Department of Urology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, People's Republic of China.
概括
抗体与药物联合体 (ADC) 结合了向单克隆抗体与强效化疗药物. 本综述考察了针对HER2阳性癌症的抗HER2ADC,讨论了已批准的疗法,临床试验和开发挑战.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 药理学 药理学是指药理学的学科.
背景情况:
- 单克隆抗体提供向癌症治疗,但缺乏足够的细胞杀伤能力.
- 抗体-药物联合体 (ADC) 将单克隆抗体与细胞毒药物结合起来,以增强抗瘤疗效.
- 人类表皮生长因子受体 (HER) 家族,特别是HER2,是癌症治疗的关键标.
研究的目的:
- 对已批准的抗HER2ADC进行审查 (T-DM1,DS-8201a,RC48).
- 分析正在进行和失败的临床试验,涉及抗HER2ADCs.
- 讨论针对HER2阳性癌症的ADC开发的挑战和未来方向.
主要方法:
- 对已批准的抗HER2ADC进行文献审查.
- 对抗HER2ADCs的临床试验数据的分析.
- 讨论ADC技术的挑战和未来前景.
主要成果:
- 三种抗HER2ADC被批准,在HER2阳性癌症中显示出前景.
- 许多临床试验正在评估抗HER2ADCs,取得了不同程度的成功.
- 开发ADC面临诸多挑战,包括链接器稳定性,有效载荷效率和阻力机制.
结论:
- 抗HER2ADCs在治疗HER2阳性恶性瘤方面取得了重大进展.
- 持续的研究对于克服ADC发展障碍和优化患者治疗结果至关重要.
- 未来的策略可能包括新的链接化学,组合疗法和克服药物耐药性.
相关概念视频
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
01:30Cancer Vaccines
363
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
363
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
01:31Hybridoma Technology
14.7K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.7K